CIK 0001133869 · Non-accelerated filer<br>Smaller reporting company
CAPRICOR THERAPEUTICS, INC.
Sign in to watch- Ticker
- CAPR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (310) 358-3200
- Business address
- 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121
- Former names
- Nile Therapeutics, Inc., SMI PRODUCTS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 97 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-08-08 | Marban Linda Chief Executive Officer | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2019-08-08 | Manzo Louis Director | Grant or award · Stock Option (right to buy) | +4,500 | 4,500 | ||
| 2019-08-08 | Krasney Karen EVP, General Counsel | Grant or award · Stock Option (right to buy) | +14,000 | 14,000 | ||
| 2019-08-08 | DUNBAR GEORGE W JR Director | Grant or award · Stock Option (right to buy) | +5,250 | 5,250 | ||
| 2018-07-24 | Ascheim Deborah Chief Medical Officer | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2018-01-02 | Smith Rachel Vice President of R&D | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2018-01-02 | Marban Linda Chief Executive Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2018-01-02 | Manzo Louis Director | Grant or award · Stock Option (right to buy) | +25,500 | 25,500 | ||
| 2018-01-02 | Krasney Karen EVP, General Counsel | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2018-01-02 | Kazam Joshua A Director | Grant or award · Stock Option (right to buy) | +18,000 | 18,000 | ||
| 2018-01-02 | DUNBAR GEORGE W JR Director | Grant or award · Stock Option (right to buy) | +28,000 | 28,000 | ||
| 2018-01-02 | Litvack Frank Director | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2018-01-02 | Musket David B Director | Grant or award · Stock Option (right to buy) | +38,000 | 38,000 | ||
| 2018-01-02 | COLLIER EARL M JR Director | Grant or award · Stock Option (right to buy) | +30,500 | 30,500 | ||
| 2018-01-02 | Ascheim Deborah Chief Medical Officer | Grant or award · Stock Option (right to buy) | +43,122 | 43,122 | ||
| 2018-01-02 | Bergmann Anthony Chief Financial Officer | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2017-12-22 | Smith Rachel Vice President of R&D | Option exercise | +20,748 | $0.16 | $3K | 20,748 |
| 2017-12-22 | Smith Rachel Vice President of R&D | Shares withheld for taxes | −2,244 | $1.48 | $3K | 18,504 |
| 2017-12-22 | Smith Rachel Vice President of R&D | Option exercise · Stock Option (right to buy) | −20,748 | 0 | ||
| 2017-10-23 | Manzo Louis Director | Option exercise | +20,748 | $0.16 | $3K | 159,132 |
Page 20 of 24 · 468 trades